Werewolf Therapeutics (HOWL) Revenue & Revenue Breakdown
Werewolf Therapeutics Revenue Highlights
Latest Revenue (Y)
$19.94M
Latest Revenue (Q)
$742.00K
Werewolf Therapeutics Revenue by Period
Werewolf Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $19.94M | 21.60% |
| 2022-12-31 | $16.40M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Werewolf Therapeutics generated $19.94M in revenue during NA 2023, up 21.60% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Werewolf Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $742.00K | -50.57% |
| 2023-12-31 | $1.50M | -74.55% |
| 2023-09-30 | $5.90M | -27.03% |
| 2023-06-30 | $8.08M | 81.03% |
| 2023-03-31 | $4.46M | -38.71% |
| 2022-12-31 | $7.28M | 46.54% |
| 2022-09-30 | $4.97M | 19.82% |
| 2022-06-30 | $4.15M | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Werewolf Therapeutics generated $742.00K in revenue during Q1 2024, up -50.57% compared to the previous quarter, and up 10.19% compared to the same period a year ago.
Werewolf Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| DBTX | Decibel Therapeutics | - | - |
| TALS | Tourmaline Bio | - | - |
| ACET | Adicet Bio | - | - |
| CYT | Cyteir Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| CELC | Celcuity | - | - |
| VOR | Vor Biopharma | - | - |
| THRD | Third Harmonic Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| CSBR | Champions Oncology | - | $12.02M |
HOWL Revenue FAQ
What is Werewolf Therapeutics’s yearly revenue?
Werewolf Therapeutics's yearly revenue for 2023 was $19.94M, representing an increase of 21.60% compared to 2022. The company's yearly revenue for 2022 was $16.4M, representing an increase of 100.00% compared to 2021. HOWL's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Werewolf Therapeutics’s quarterly revenue?
Werewolf Therapeutics's quarterly revenue for Q1 2024 was $742K, a -50.57% decrease from the previous quarter (Q4 2023), and a -83.38% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.5M, a -74.55% decrease from the previous quarter (Q3 2023), and a -79.39% decrease year-over-year (Q4 2022). HOWL's quarterly revenue for Q3 2023 was $5.9M, a -27.03% decrease from the previous quarter (Q2 2023), and a 18.65% increase year-over-year (Q3 2022).
What is Werewolf Therapeutics’s revenue growth rate?
Werewolf Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.